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Abstract Post-marketing drug surveillance for adverse
drug events (ADEs) has typically relied on spontaneous
reporting. Recently, regulatory agencies have turned their
attention to more preemptive approaches that use existing
data for surveillance. We conducted an environmental
scan to identify active surveillance systems worldwide
that use existing data for the detection of ADEs. We
extracted data about the systems’ structures, data, and
functions. We synthesized the information across systems
to identify common features of these systems. We iden-
tified nine active surveillance systems. Two systems are
US based—the FDA Sentinel Initiative (including both the
Mini-Sentinel Initiative and the Federal Partner Collabo-
ration) and the Vaccine Safety Datalink (VSD); two are
Canadian–the Canadian Network for Observational Drug
Effect Studies (CNODES) and the Vaccine and Immuni-
zation Surveillance in Ontario (VISION); and two are
European–the Exploring and Understanding Adverse Drug
Reactions by Integrative Mining of Clinical Records and
Biomedical Knowledge (EU-ADR) Alliance and the
Vaccine Adverse Event Surveillance and Communication
(VAESCO). Additionally, there is the Asian Pharmaco-
epidemiology Network (AsPEN) and the Shanghai Drug
Monitoring and Evaluative System (SDMES). We identi-
fied two systems in the UK—the Vigilance and Risk
Management of Medicines (VRMM) Division and the
Drug Safety Research Unit (DSRU), an independent aca-
demic unit. These surveillance systems mostly use
administrative claims or electronic medical records; most
conduct pharmacovigilance on behalf of a regulatory
agency. Either a common data model or a centralized
model is used to access existing data. The systems have
been built using national data alone or via partnership
with other countries. However, active surveillance systems
using existing data remain rare. North America and Eur-
ope have the most population coverage; with Asian
countries making good advances.
Key Points
We systematically conducted an inventory of
ongoing initiatives that use large-linked databases
for active drug safety evaluation
Active surveillance systems for adverse drug events
remain rare, but electronic health data are likely to
increase the feasibility of active surveillance
Currently, the systems supplement existing adverse
drug reaction reporting systems, by amplifying and/
or refining safety signals. Signal generation without
pre-specified safety questions is uncommon
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1 Background
For decades, post-marketing drug safety surveillance has
depended on analysis of spontaneous adverse drug events
(ADEs). Systems such as the FDA Adverse Event Report-
ing System (FAERS) in the USA and the World Health
Organization (WHO) Programme for International Drug
Monitoring [1, 2] were established to improve post-mar-
keting surveillance for ADEs. However, the system relies
on voluntary reporting by healthcare professionals or
patients and their families. In many countries, including the
USA, the law requires pharmaceutical and medical device
manufactories to report ADEs to the drug regulatory
authorities [3]. These spontaneous reporting systems, nev-
ertheless, are hampered by incomplete information in the
reports, such as on the exposures or outcomes, which limit
the value of the data. [4]. Additionally, the healthcare
community often fails to report events with well-established
causality, diminishing our ability to establish the prevalence
of ADEs with passively reported data. Moreover, there is
under-reporting of events that are not hypothesized to be
drug related, unless the events are very severe.
Given the deficiencies inherent in systems that rely on
spontaneous ADE reporting, there are many proactive
approaches to study the causal relationship between medical
interventions and harmful effects. For example, in the
Netherlands, the Lareb Intensive Monitoring’s web-based
tool collects primary information from patients for phar-
macovigilance [5]. Other strategies include the use of case-
control networks to identify ADEs or hospital-based inten-
sive monitoring systems [6]. Yet, there is ongoing interest in
developing systems that can incorporate and use existing
electronic data such as administrative claims and electronic
health record (EHR) data to enable active surveillance for
ADEs [7]. The latter method can be efficient, as it does not
require the collection of new information. It enables inves-
tigators to actively query existing information, and provides
a more holistic picture of drug use in a community.
Drug regulatory agencies and the pharmaceutical
industry in the USA and many European countries are
vigorously developing active surveillance systems for
pharmaceutical products, vaccines, and medical devices
[8]. We aimed to review the status of active surveillance
systems for the detection of ADEs, worldwide, with the
goal of informing communities considering active sur-
veillance for ADEs in their population.
2 Methods
We conducted an environmental scan to identify active
surveillance systems. In brief, we relied on a search of the
published literature to identify citations describing active
surveillance systems. We also searched online for evidence
of other active surveillance systems, not detected in our
published literature review. We then identified the best
sources of information about these systems and extracted
this information into tables. Additionally, we sought the
input of experts who have been key leaders in active sur-
veillance systems in the USA to review our list of systems
and suggest missed active surveillance systems for incor-
poration in this review.
2.1 Key Components
The key components of the active surveillance systems that
we sought to capture with this environmental scan were:
Structure—The structure, partnership relationships, and
funding of existing active surveillance systems; Data—The
data used in existing surveillance systems, what patient
populations are included, and what is the content of these
data; Function—Examples of ADEs that have been iden-
tified with the active surveillance systems.
2.2 Scanning Strategy
A literature search was conducted to identify articles con-
taining information on active surveillance systems from
electronic databases PubMed, Google Scholar, and EM-
BASE from 2003 to 2013 on October and November 2014
(see electronic supplementary material Tables 1 and 2).
We searched using MeSH terms and key word searches
relevant to this topic including: ‘‘product surveillance,
‘‘postmarketing’’, ‘‘pharmacovigilance’’, ‘‘adverse drug
event’’, ‘‘adverse drug reaction reporting systems’’ [MeSH
Terms], and ‘‘database management systems.’’ No lan-
guage barrier was set for the query, but the abstract
required a title and abstract in English. We also searched
for citations describing known active surveillance systems
such as the Sentinel Initiative and Exploring and Under-
standing Adverse Drug Reactions by Integrative Mining of
Clinical Records and Biomedical Knowledge (EU-ADR).
We supplemented this with searches using online search
engines (Google and Bing) to identify references to active
surveillance systems that we had not found in the profes-
sional literature.
2.3 Review Strategy
Paired authors reviewed the titles of the citations identified
in the electronic search for relevance to active surveillance.
If any single author thought it to be potentially relevant, it
was retrieved for further review. We did not seek to
identify every article that described a given active sur-
veillance system—a single article that alerted us to the
presence of the system was sufficient. We created a




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comparison of Active Adverse Event Surveillance Systems 585
working definition for the purposes of the scanning exer-
cise. For our review, an active surveillance system has the
following features (the first four were adapted from the
work by Aronson and colleagues) [9]:
• It is designed for post-marketing surveillance of
pharmaceutical products (including vaccines).
• It has a goal of generating post-marketing drug safety
information.
• It does not require personnel to initiate safety reports
(describing individual cases).
• It uses real-world data that are generated from routine
practice, requiring no direct patient contact.
• Data cannot be from a single institution.
The three authors came to a consensus about the active
surveillance systems that would be described in the envi-
ronmental scan based upon their meeting the criteria descri-
bed above. We opted to exclude studies conducted in single
institutions because we expected that these operations would
not have had the challenge of integrating data from various
sources, which is typical of most active surveillance systems.
2.4 Data Extraction
The authors identified the published articles or online
sources with sufficient information to populate the data
tables. Frequently, more than one source was needed to
identify the relevant information. Data were extracted into
table shells that were developed to describe the key com-
ponents of the active surveillance systems.
3 Results
We identified nine active surveillance systems meeting our
criteria worldwide. (Table 1) Most systems are in North
America and Europe. We first provide an overview of the
systems and then describe commonalities across systems.
3.1 Regional Overview of Pharmacovigilance Systems
Worldwide
3.1.1 Asia
In Asia, the Shanghai Center for Adverse Drug Reaction
Monitoring has led the Shanghai Drug Monitoring and
Evaluative System (SDMES) since 2001. The SDMES is
an evaluation and surveillance system designed for the
local monitoring of marketed drugs. It works in partnership
with ten hospitals in Shanghai that permit direct access to
patient information.
Other countries in Australasia (Japan, Korea, Taiwan,
and Australia) have taken a different approach. They
formed a voluntary research network, the Asian Pharma-
coepidemiology Network (AsPEN) [10]. Recently, the
USA, Sweden, Hong Kong, China, and Singapore have
become collaborators with AsPEN. This cross-national
endeavor aims to facilitate identification and validation of
emerging safety issues for pharmaceutical products across
Asian countries.
3.1.2 Canada
In response to the Food and Consumer Safety Action Plan,
which was designed to strengthen consumers’ health,
Health Canada formed the Drug Safety and Effectiveness
Network (DSEN). The DSEN, on behalf of Health Canada,
and the Canadian Institutes of Health Research (CIHR)
began the Canadian Network for Observational Drug Effect
Studies (CNODES) in March 2011. CNODES is tasked
with coordinating drug safety and effectiveness research
for drugs approved for sale in Canada [11, 12]. The
CNODES established a network that brings together
researchers, as well as databases, from provinces across
Canada. Aside from the Canadian provincial databases,
CNODES also accesses the UK’s Clinical Practice
Research Datalink (CPRD; formerly GPRD) as this allows
CNODES to investigate drugs marketed in the UK before
they are launched in Canada.
Before the establishment of CNODES, the Institute for
Clinical Evaluative Sciences (ICES) created the Vaccine
and Immunization Surveillance in Ontario (VISION) as a
vaccine vigilance system. The ICES is a healthcare and
health services research institute in Ontario, and also
houses Ontario’s healthcare claims data [13].
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3.1.3 European Union
There has been important legislation regarding drug safety
in Europe. In 2010, the European Union (EU) adopted new
pharmacovigilance regulations that strengthened coordi-
nation and data collection—Directive 2010/84/EU and
Regulation 1235/2010. Since this legislation, the European
Medicines Agency (EMA) can charge a fee to pharma-
ceutical companies specifically for the costs of pharmaco-
vigilance systems, and the systems can move forward
providing holistic examination of drug safety.
The EMA piloted a project, EU-ADR, which imple-
mented a computerized system to detect ADEs with
extracted EHRs between 2008 and 2012[14]. It developed
standardized procedures and software for extraction and
aggregation of data from multiple sources in different
European countries, developed methods for pooled data
analysis, and established a web platform as an open
workspace for the integrated analysis. Based on the system
developed during the EU-ADR project, the EU-ADR
Alliance emerged as a federated collaborative framework
for drug safety studies, using eight European population-
based administrative and healthcare databases from Italy,
Netherlands, UK, Germany, and Denmark [15].
Additionally, since 2008, the European Centre for Dis-
ease Prevention and Control (ECDC) has funded a con-
sortium of researchers in EU countries. This supported
VAESCO: Vaccine Adverse Event Surveillance and
Communication (VAESCO), which was established to
study ADEs following immunization [16, 17]. VAESCO’s
most recent activity was in 2012 when it completed a
project studying narcolepsy after influenza vaccines.
3.1.4 United Kingdom
The UUK has two active systems: the Vigilance and Risk
Management of Medicines (VRMM) and the Drug Safety
Research Unit (DSRU). As part of Medicines and Health-
care products Regulatory Agency, the VRMM maintains
ongoing activities to monitor the safety of marketed medi-
cines [18]. VRMM is also involved in pharmacoepidemi-
ology, research and intelligence, and benefit-risk review
[18]. VRMM has implemented proactive pharmacovigi-
lance by the expert use of CPRD—the large-linked obser-
vational datasets from a range of primary and secondary
care settings. This along with its ‘‘Yellow Card’’ scheme, a
spontaneous reporting system, allows it to conduct a com-
prehensive review of selected healthcare products [19].
The DSRU was founded in 1980 as an independent aca-
demic unit and has been conducting post-marketing surveil-
lance, pharmacoepidemiology, and risk management studies
across Europe. It uses diverse European data for pharmaco-
vigilance, but predominantly data from the UK. Investigators
in the DRSU developed a novel method for early detection of
unrecognized drug hazards of newly marketed drugs, known
as prescription-event monitoring (PEM) [20]. In the late
1990s, DSRU established an updated version of PEM, Mod-
ified PEM (M-PEM), which surveys general practitioners. For
their investigations, they target a sample of 10,000 patients
prescribed a given drug, and link prescription data to census
data and healthcare databases [21].
Although the DRSU is fundamentally different than the
other systems we included in this review, the M-PEM
method of DSRU met our criteria for active surveillance.
The process requires that general practitioners complete
questionnaires and send them back to DRSU; however, this
is a systematic process employed when there is a suspected
adverse event (this is not case reporting). General practi-
tioners are randomly selected to respond to questionnaires.
We consider this to be active surveillance because nearly
all UK residents are registered to general practitioners and
data on nearly all prescriptions issued by general practi-
tioners are sent by pharmacists to the Prescription Pricing
Authority, which is responsible for reimbursement.
Because DSRU targets all prescriptions that were issued
since the launch of the drug of interest, it can be considered
as an active post-marketing surveillance system.
3.1.5 USA
In response to the Food and Drug Administration
Amendment Act of 2007, the US FDA has collaborated
with public, academic, and private entities to develop a
national electronic safety monitoring system, the Sentinel
Initiative. Several projects were initiated under the Sentinel
Initiative to augment existing safety monitoring systems.
The Foundation for the National Institutes of Health
launched the Observational Medical Outcomes Partnership
(OMOP) in late 2008 as a 2-year pilot project to identify
the needs of the Sentinel Initiative and to develop the
essential methods and data infrastructure to allow the reuse
of automated healthcare data [22].
Harvard Pilgrim Health Care Institute coordinated a
pilot project, the Mini-Sentinel. The Mini-Sentinel’s
objective is to develop the framework, data resources,
analytic capabilities, policies, and procedures that will be
required for a fully operational Sentinel System [23]. In
addition to pharmaceutical product surveillance, the Mini-
Sentinel also includes the Post-Licensure Rapid Immuni-
zation Safety Monitoring (PRISM) project and the Blood
Safety Continuous Active-Surveillance Network Feasibil-
ity Evaluation (Blood-SCAN) project. Blood-SCAN fulfils
the regulatory need for maintaining a safe blood supply
[24]. Although the Mini-Sentinel Initiative officially ended
in September 2014, the contract was been changed to be a
new 5-year cooperative agreement. Furthermore, a new
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public–private partnership, the Innovation in Medical
Evidence Development and Surveillance (IMEDS), was
established to build on the work of the Mini-Sentinel and
OMOP to enhance post-marketing pharmacovigilance and
facilitate the use of EHRs [25].
The FDA also cooperates with Veteran’s Affairs, the
Department of Defense, and the Centers for Medicare and
Medicaid Services on the Federal Partner Collaboration
(FPC), which provides access to federally owned health-
care data [26]. This collaboration allows the FDA to assess
the safety and effectiveness of products in unique and
potentially vulnerable populations.
The VSD predates the Sentinel Initiative. Since 1990,
the VSD, managed by the Centers for Disease Control and
Prevention (CDC), has been providing evidence, particu-
larly about safety, to inform national immunization policy
through population-based research [27]. With more than 2
decades of surveillance, the VSD has repeatedly demon-
strated its ability to investigate and detect safety signals,
and evaluate vaccine effectiveness [28].
3.2 Structure of the Active Surveillance Initiatives
The initiatives described above are mostly research net-
works or institutes; some are public–private collaborations.
Only the VRMM (UK) and the SDMES (China) are
administered through government agencies. However,
nearly all receive funding from public sources (Table 1).
Only AsPEN (Asia) does not have an identifiable funding
source [29]; the DSRU (UK) is the only one that receives
funding mainly from the private sector.
Each system has a somewhat different operational
structure. DSRU (UK) is a registered independent charity
that receives support from the National Health Service
(NHS) Business Service Authority. The DSRU also
receives unconditional donations from pharmaceutical
companies. The DSRU has authority to access and uses
patient-identifiable data without patient consent based on
the permission from the Ethics and Confidentiality Com-
mittee of the NHS National Information Governance Board.
The USA took a public–private approach to data.
Because there is no universal public insurance coverage,
both the Sentinel Initiative and VSD cooperate with private
insurers as data partners. The CDC’s Immunization Safety
Office partners with managed care organizations through-
out the USA to allow the VSD to rapidly detect adverse
events after immunization [27].
In the Sentinel Initiative’s Mini-Sentinel Pilot (USA),
Harvard Pilgrim Health Care Institute serves as the coor-
dinating center and collaborates with multiple private
insurance plans as data partners [30, 31]. The Sentinel
Initiative’s Federal Partners Collaborative includes the
Center for Medicare and Medicaid Services, the Veterans
Administration, and the Department of Defense, which
allows this Collaborative to query federally held, electronic
healthcare data.
Many initiatives adopt a collaborative approach by
engaging researchers from multiple institutes such as the
EU-ADR Alliance (EU), the CNODEs (Canada), and the
AsPEN (Asia). The approach may be an efficient and
flexible way to initiate safety studies. In the mechanisms of
CNODES and EU-ADR Alliance, the regulatory authori-
ties (EMA and Health Canada) pose study questions
regarding drug safety and effectiveness to the study coor-
dinating office. In CNODES, other federal agencies and
health plans can submit their questions to Health Canada
[11]. Then, the scientific advisory committee evaluates and
sets up a research agenda, and a project team is formed to
answer the question. In the AsPEN, participating
researchers achieve census on the pressing study questions
regarding drug safety [10], and then teleconferences are
held to develop protocols and to decide on the study exe-
cution details.
3.3 Data
The initiatives generally rely on existing population-based
data; most use administrative claims (Fig. 1; Table 2).
Many also have the ability to link to medical records.
Death and cancer registries are anonymously linked within
the provinces in Canada [13]. The source of exposure data
for the VSD (USA) comes from the automated systems of
managed care organizations that track immunizations
administered to members [32]. For evaluating vaccine
safety, all of the vaccine surveillance systems link medical
records to vaccine registries.
The large-linked databases have rich information
(Fig. 2). The databases contain demographic information
and prescription information. Except for the SDMES
(China), the other initiatives can capture longitudinal
information on medical use from outpatient records effec-
tively, but are less able to aggregate inpatient data. The
SDMES (China) uses medical records directly from hos-
pitals, but cannot access outpatient information. Software
is installed in each hospital’s information system to capture
required information, and information is sent to the
SDMES center periodically [33]. The CPRD used by the
VRMM (UK) allows for the tracking of medical activity
and drug use seamlessly. Because of the rich information
contained in EHRs, most initiatives are actively working to
capture and incorporate this into their data, so that they
have laboratory results and richer clinical information than
can be known from claims data.
Legal and privacy has been an important concern in
many countries, such as the Health Insurance Portability
and Accountability Act (HIPAA) in the USA. Most
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initiatives choose not to pool data directly from multiple
databases in a single central warehouse. Most initiatives
chose a distributed data network approach, meaning most
data remain in situ, and data partners have ownership and
physical control of their protected data. In many initiatives,
data are owned by different entities, for example, in the
Mini-Sentinel (USA), data are owned by the different
health plans; in the EU-ADR Alliance, data are owned by
either government agencies or research institutes. Because
of the concerns about the control of data, the VSD (USA)
moved from using a central repository of data to distributed
data storage [34]. Distributed data storage also facilitates
collaboration across countries as is seen in the AsPEN
(Asia) and the EU-ADR Alliance.
To aggregate data across sites, many initiatives use a
common data model or common protocol. In CNODES
(Canada) and the Federal Partner Collaborative (USA),
common protocols are developed to standardize data
queries and analyses in each database. Local content
experts remain involved throughout the process. In
CNODES, content experts are included in each project
team [11].
The Mini-sentinel (USA), EU-ADR (EU), AsPEN
(Asia), and VSD (USA) have developed their own common
data models so that they can standardize data queries and
perform analyses locally with pre-specified statistical
packages. The common data model consists of separate
tables, each of which stores a specific type of data
Fig. 1 Types of databases used
in worldwide active surveillance
systems. The Federal Partners
Collaboration and Mini-Sentinel
are counted separately, and
systems may use multiple types
of databases. EHR electronic
health records, PBM pharmacy
benefits manager
Fig. 2 Characteristics of data
elements used in worldwide
surveillance systems. The
Federal Partners Collaboration
and Mini-Sentinel are counted
separately. The percentage of
each data element is calculated
based on available data in each
category. Additionally,
vaccination surveillance
systems were not calculated in
‘‘drug codes’’ and ‘‘quantity’’
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generated from a query. Using a common data model,
standardized common input files are generated locally by
each data partner. An internal identifier is included in the
input files so that each unique patient can be linked across
local files, providing a comprehensive medical history
during the period the patient receives care from that
institution or is enrolled in that insurance plan. The coor-
dinating centers typically develop standard statistical
packages that are distributed to each site that contributes
data. The aggregated, de-identified, and encrypted files,
which include patient, drug, and event information, are sent
to a central repository for further evaluation and analysis.
Sometimes, only the results of local analyses are trans-
mitted centrally. Jerboa, used by the EU-ADR Alliance, is
a custom-built JAVA software developed to query and
analyze local patient data [14].
Initiatives with smaller populations, such as VISION
(Canada) and SDMES (China), have chosen central data
models. Moreover, the methods of data collection for the
CPRD (from general practitioners in the UK) necessarily
make these central databases. There are several methods to
link patient data in a central model. If they are used across
multiple systems, the most straightforward way is to use
deterministic linkage, based on unique personal identifiers.
The SDMES and CPRD use this approach to generate
comprehensive patient-level histories. The CPRD uses the
universally adopted NHS number to link patients’ data
from general practitioners to hospital medical records.
Another approach is to use probabilistic record linkage,
which is adopted by one of the EU-ADR Alliance dat-
abases, the PHARMO database. The probabilistic record
linkage uses Bayesian likelihood estimations and learning-
based rules to estimate the likelihood that two files belong
to the same person [35].
Unlike other systems that use EHRs or claims data, the
DSRU (UK) collects prescription information from the
government and collects questionnaire-based responses
from primary care doctors in their data warehouse. This
approach incorporates both retrospective and prospective
data collection.
For initiatives that involve multi-institutional collabo-
ration, there are assorted data harmonization processes in
place. For example, the EU-ADR Alliance uses databases
having different characteristics, so the Unified Medical
Language System (UMLS) is used to map different ter-
minologies [36]. The PRISM (in the US Mini-Sentinel)
chose to use the HL7 system and applied this to acquire
standardized information from different data partners.
In some cases, use of a distributed data network delays
access to data if there are many involved sites. In the FPC
(USA), claims data are updated weekly, and prescription
drug claims are updated monthly. However, it may take up
to 2 years for drug data in the standard analytical files of
the FPC to be available to the research community [37].
The VSD (USA) and Mini-Sentinel (USA) can refresh data
files weekly and quarterly, respectively. The VSD devel-
oped a real-time surveillance system and initiated its use in
an ongoing study of a new meningococcal vaccine for
adolescents [38]. The VSD’s rapid cycle analysis approach
uses relatively simple structured and aggregated data for
weekly analyses; data are segmented into weekly cohorts
of vaccinated children. More accurate data are then avail-
able after 8 weeks.
3.4 Function–Examples of Safety Events Evaluated
Currently, all of the initiatives investigate safety questions
in response to regulatory agencies’ requests. Active sur-
veillances play supportive roles to spontaneous systems
and do not aim to replace them. Most surveillance systems
see their role as signal refinement rather than signal
detection, although the vaccine ADE systems aim to detect
safety signals (Table 3).
Maximized sequential probability ratio testing (max-
SPRT) is one of the commonly used techniques and has
been used in the VRMM’s (UK) enhanced proactive
pharmacovigilance, as well as by the Mini-Sentinel and the
VSD (USA) [39]. MaxSPRT supports continuous or time-
period analyses as data are collected, and allows detection
of a change in the probabilities of ADEs after the intro-
duction of a new vaccine or drug [38]. The VSD has used
maxSPRT to analyze its weekly updated data for real-time
surveillance since 2005 [40]. VSD has studied the associ-
ation between quadrivalent human papillomavirus vaccine
and venous thromboembolism [41].
The Mini-Sentinel team developed the Cohort Matching
Prospective Routine Observational Monitoring Program
Tool (PROMPT) module, which is a suite of modular SAS
macros that enables effect estimation in distributed data,
using a propensity-score-matched sequential cohort of new
users of the drug under investigation [42]. It allows the
FDA to investigate prespecified health outcomes in newly
marketed pharmaceutical and biological products. Mini-
Sentinel investigators have been monitoring a wide range
of products; an example is the surveillance for ischemic
stroke, intracranial hemorrhage, and gastrointestinal
bleeding in new users of rivaroxaban compared with users
of warfarin [43].
The VRMM (UK) has developed methods for near real-
time sequential analysis of ADE reports that come in from
its Yellow Card scheme. Epidemiological analyses using
the CPRD are then used to refine and evaluate these safety
signals [19]. The team has evaluated the association
between bivalent human papillomavirus vaccine (Cervarix)
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and fatigue syndromes with an ecological and a self-con-
trolled case series design [19]. The DSRU (UK) using its
M-PEM technique evaluated the safety of rimonabant,
which was suspected of causing depressive episodes. By
comparing the risk of major and minor depressive episodes
before and after initiation of rimonabant, DSRU concluded
that rimonabant causes depressive episodes in patients
without a previous psychiatric history [44].
Disproportionate reporting is a methodology use by
EudraVigilance, part of the EU-ADR Alliance. Based on a
signal detected with disproportionate reporting analyses,
the EU-ADR Alliance developed a research protocol to
investigate the association between risk of cardiac valve
disorders and the use of bisphosphonates, in response to
EMA’s request [45]. Main analyses employed data mining
techniques to explore the association with automated
matched case-control methods [45].
CNODES (Canada) developed a research protocol
according to Health Canada’s request to evaluate the
association between the use of high-potency statins and
acute kidney injury [46]. This study used a nested case-
control analysis with propensity-score adjustment. Another
study testing the association between proton pump inhibi-
tors and pneumonia used high-dimensional propensity
scores to match exposed and control groups [47]. Cohort,
case-control, risk-interval, and self-controlled case-series
designs are often used to assess vaccine safety [48]. The
VISION (Canada) researchers have used the linked data for
self-controlled case-series analyses to investigate the
association between vaccination and emergency room
visits, hospital admissions, and deaths [13].
The Mini-Sentinel (USA) has investigated the associa-
tion between rotavirus vaccination and intussusception
with a self-controlled risk-interval and cohort design in its
PRISM program [49]. With access to data on so many
exposed individuals, the research team had sufficient power
to answer the FDA’s query. The FDA later required revised
labeling for RotaTeq [50]. VAESCO (EU) studied the
safety of Pandemrix, a monovalent 2009 H1N1 influenza
vaccine [51]. The researchers chose a retrospective case-
control design. As the results could not demonstrate a
strong association between vaccination of Pandemrix and
narcolepsy, the EMA concluded that the benefits still out-
weigh the risk with Pandemrix [52, 53].
3.5 Limitations in Current Initiatives
Accurate identification of adverse health outcomes and
medicine use is critical in any active surveillance systems.
All of the initiatives largely use existing data, which means
the data are not collected primarily for research purposes.
Therefore, each initiative needs to take steps to ensure the
validity of coding. The Mini-Sentinel, CPRD, and EU-
ADR have made great efforts to validate algorithms to
identify health outcomes of interest in given datasets [54–
58]. The researchers have used external sources to confirm
health outcomes, but the validity varies widely. In the
Mini-Sentinel, investigators found positive predictive val-
ues in the range of 25 % (for liver disease) to 66 % (for
anaphylaxis); in CPRD, confirmed diagnoses among stud-
ies were in the range of 24–100 %.
Many initiatives that use EHR data have limited ability
to analyze very new products. Part of the success of the
Mini-Sentinel project came from learning from vaccine
surveillance. However, there are significant differences
between surveillance of vaccines and of drugs. One
important factor is the time for diffusion of use of new
products into the market. Vaccines are often funded by the
public sector and made widely available so there is less
difficulty in having enough exposed individuals to study.
Because most of the systems use insurance healthcare
databases, delayed uptake of new drugs owing to lack of
coverage or formulary restrictions, means that sufficient
users of a new medication may not be available for study.
Although some initiatives are using EHR data, the
overall use of EHR is low; most of the data being used are
from administrative claims. Thus, the ability to study out-
comes and ADEs that require analysis of laboratory results
is limited. Detection of ADEs such as liver injury is
challenging with claims data alone.
The Sentinel Initiative, EU-ADR, and AsPEN employed
a common data model to aggregate data, but use of a
common data model may result in some loss of data
integrity. When researchers tested the OMOP common data
model in the THIN database, they mapped medical and
drug codes. Twenty-five percent of the diagnosis codes and
55 % of the drug codes in the raw THIN database were not
retrieved with the OMOP terminology dictionary [59].
Continuing work is needed to improve application of
algorithms across different data sources.
Active surveillance is a resource-intensive task. Active
surveillance systems require advanced information tech-
nology infrastructure to store and process analyses. The
EMA and pharmaceutical industry contributed 6 million
Euros to the 4-year EU-ADR project [60]. The FDA
awarded a 5-year contract to the Harvard Pilgrim Health
Care Institute to carry out the Mini-Sentinel pilot project
for 72 million US dollars [61]. The New Zealand Phar-
macovigilance Centre at the University of Otago operated
the Intensive Medicines Monitoring Programme for PEM,
and has been suspended because of a lack of funding [62].
The case needs to be made that there is a public health
value to these systems and this needs to be demonstrated
with data.
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4 Discussion
4.1 Summary of Findings
A number of review articles have discussed individual
systems separately [23, 32, 63, 64], our report may be the
first to systematically describe the worldwide, active drug
surveillance systems that use existing data. We have found
that while databases of healthcare information are increas-
ingly prevalent, there are relatively few countries involved
in active surveillance and these are largely in North
America and Europe. We identified no systems that cover
medication-exposed patients in India, the Eastern European
countries, or the South American and African continents.
Other systems are early in development and are promising.
We propose that the most successful systems are those able
to accurately and efficiently capture prescription and use
data, can refresh information frequently, have easy access to
experts for advanced statistical analyses, and have a large
patient population from which to draw data.
There is no single way to success. Diverse approaches
are taken to conduct active surveillance because of dif-
ferent healthcare systems. We note that the VSD (USA) is
the oldest system and has decades of experience in active
postmarketing vaccine surveillance; this has importantly
informed the development of later systems. The VRMM
(UK) has, perhaps, the greatest ability to capture medical
use comprehensively, because of their use of the long-
established and very rich CPRD data. The centralized
model adopted by the UK, the decentralized model adopted
by the USA, and the research network approach adopted by
Canada are valuable models of different approaches that
might be taken to accomplish ADE surveillance. Similarly,
the innovative collaborative model of AsPEN (Asia) is
another approach to regional pharmacovigilance, which
addresses participating countries’ needs.
4.2 Other Initiatives
We note that there have been other endeavors to detect
safety signals without relying on spontaneous reports; these
include the Immunogenicity Surveillance Registry of
Erythropoiesis Stimulating Agents in Thailand, the North
American Antiepileptic Drug Pregnancy Register in the
USA, and activities with the Australian Rheumatology
Association Database [65–67]. These did not meet our
criteria for active surveillance systems, but have many
similar characteristics. Large-linked databases have
appropriately gained attention given their tremendous
potential for safety surveillance. An example is the open
source initiative, the Observational Health Data Sciences
and Informatics (OHDSI), which is housed at Columbia
University [68]. This multi-stakeholder interdisciplinary
collaborative aims to enhance the value of observational
health data by using large-scale analytics. OHDSI applies
methods to observational data aimed at answering real-
world clinical questions, including about drug safety. There
are many similar examples.
Another system with great similarities to those reviewed
here is the Medical Information for Risk Assessment Ini-
tiative (MIHARI) initiated by the Japanese government
with the Pharmaceuticals and Medical Devices Agency.
The MIHARI project aims to develop a system that can
access electronic health information from different sources,
develop pharmacoepidemiological methodology for eval-
uating ADEs, explore existing healthcare databases for
pharmacovigilance, and create a central data database with
linked electronic health information and a common data
format such as HL7 [69]. When implemented, we expect
that this will meet our criteria for active surveillance, but it
is not yet fully functional.
The EMA also carries out two initiatives that are not
pharmacovigilance systems but support the pharmacovigi-
lance activities of the EU-ADR. The Pharmacoepidemio-
logical Research on Outcomes of Therapeutics by a
European ConsorTium (PROTECT) program and the
European Network of Centres for Pharmacoepidemiology
and Pharmacovigilance (ENCePP) project both aim to
strengthen capacity for post-authorization drug safety
research.
4.3 Limitations and Strengths
Many initiatives are still developing and growing quickly.
Some systems have limited public information; extensive
information about the systems could not easily be known.
Although the Sentinel System provides extensive detail
about their data model, this was diffcult to obtain from
most of the other systems. We collected data from multiple
sources and used a systematic approach for deciding which
systems would and would not be described. We used
established criteria and a protocol for determining what
would be considered an active surveillance system. We
searched not only for published literature but also reviewed
the national regulatory agencies’ official websites. More-
over, all information was reviewed by two authors to
ensure the reliability of the data extracted.
4.4 Future Research
Systems that use automated healthcare data to enhance
drug safety evaluation are developing rapidly. Hence, it is
necessary to re-evaluate the development of active sur-
veillance systems frequently. More global efforts are nee-
ded to build capacity and facilitate a proactive approach to
ADE evaluation [70]. A collaborative platform, such as
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what the WHO Collaborating Centre for International Drug
Monitoring-Uppsala Monitoring Centre uses for sponta-
neous reporting, could be set up so that stakeholders from
industry, regulators, and academia are able to collaborate
on pharmacovigilance using existing healthcare data.
Universal data standards such as HL7 could improve
data integration and help research activity to move
beyond its current scope. Developing new methodology
is critical for the analysis and interpretation of large real-
world data. Current initiatives are not yet entirely ready
to perform data mining and signal generation through
automatic process. Presently, most tasks done with large
data are signal refinement or evaluation and hypothesis
testing.
4.5 Conclusions
Our paper provides an inventory of ongoing initiatives
exploring large-linked databases worldwide for actively
collecting data for drug safety evaluation. Currently, the
systems are mostly used to supplement existing ADE
reporting systems by amplifying or refining safety signals.
Signal generation without a pre-specified safety research
question is not yet readily available. Fast-growing infor-
matics capacities will strengthen the ability of researchers
to evaluate drug safety after licensing.
North America and Europe have the most developed
systems and most coverage of the population, owing to
developed healthcare and information systems. Although
most computerized databases were not established for
research purposes, they have been widely used in health-
care research. Published research shows that active sur-
veillance can be an important component of drug safety
evaluation. However, methodology for this area is still
developing. Hence, caution is needed when interpreting the
result from real-world data given all of the inherent biases
when using observational data. There are challenges with
using healthcare databases for ADE surveillance, but the
prospect of using these systems to support post-marketing
regulatory decision making is promising. A global safety
strategy with a life-cycle, risk management model becomes
more and more feasible.
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